Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

24.59
-1.2500-4.84%
Pre-market: 24.00-0.5900-2.40%07:00 EDT
Volume:3.87M
Turnover:96.18M
Market Cap:305.09M
PE:-2.58
High:25.74
Open:24.96
Low:24.19
Close:25.84
Loading ...

Nektar upgraded to Buy from Hold at Jefferies

TIPRANKS
·
11 Apr

Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding

Simply Wall St.
·
04 Apr

BRIEF-Nektar Therapeutics - Enters Equity Distribution Agreement Up To $75 Million - SEC Filing

Reuters
·
29 Mar

Nektar Therapeutics - Enters Equity Distribution Agreement up to $75 Million - SEC Filing

THOMSON REUTERS
·
29 Mar

Nektar Therapeutics - to Pay 3.0% Commission Fee to Piper and Btig - SEC Filing

THOMSON REUTERS
·
29 Mar

Nektar Therapeutics Files $300 Million Mixed Shelf

MT Newswires Live
·
29 Mar

Nektar files $300M mixed securities shelf

TIPRANKS
·
29 Mar

BRIEF-Nektar Therapeutics Files For Mixed Shelf Offering Of Up To $300 Million - SEC Filing

Reuters
·
29 Mar

Nektar Therapeutics: Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing

THOMSON REUTERS
·
29 Mar

Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil

Insider Monkey
·
23 Mar

Nektar Therapeutics Shares Rise After Upgrade From Oppenheimer

MT Newswires Live
·
15 Mar

Nektar Therapeutics Raised to Outperform From Perform by Oppenheimer

Dow Jones
·
14 Mar

Nektar Therapeutics : Oppenheimer Raises to Outperform From Perform

THOMSON REUTERS
·
14 Mar

Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)

Zacks
·
14 Mar

Oppenheimer Upgrades Nektar Therapeutics to Outperform From Market Perform, Price Target is $6

MT Newswires Live
·
14 Mar

Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
14 Mar

Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up

Zacks
·
14 Mar

Q4 2024 Nektar Therapeutics Earnings Call

Thomson Reuters StreetEvents
·
14 Mar

Nektar Therapeutics Price Target Maintained With a $6.50/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

William Blair Sticks to Their Hold Rating for Nektar Therapeutics (NKTR)

TIPRANKS
·
13 Mar